I will honestly be be shocked if this baby doesn’t double within a few days of IPO 1) A phenomenal team steering the ship - Also being supported by a few heavy hitters such as Asia Cornerstone Asset Management 2) A track record of FDA approvals 3) Promising technology that will give them access to a 6.2B AUD market 4) It actually has decent revenue behind it...unlike the majority of these Pharma IPO’s as of late.
